JTO Clinical and Research Reports, Journal Year: 2024, Volume and Issue: 6(3), P. 100781 - 100781
Published: Dec. 18, 2024
Language: Английский
Molecular Aspects of Medicine, Journal Year: 2024, Volume and Issue: 96, P. 101254 - 101254
Published: Feb. 13, 2024
Language: Английский
Citations
5
Trends in Immunology, Journal Year: 2024, Volume and Issue: 45(7), P. 486 - 494
Published: June 13, 2024
Language: Английский
Citations
5
Vaccines, Journal Year: 2024, Volume and Issue: 12(6), P. 655 - 655
Published: June 12, 2024
Glioblastoma (GBM) is the most common and aggressive malignant brain tumor. Standard treatments including surgical resection, radiotherapy, chemotherapy, have failed to significantly improve prognosis of glioblastoma patients. Currently, immunotherapeutic approaches based on vaccines, chimeric antigen-receptor T-cells, checkpoint inhibitors, oncolytic virotherapy are showing promising results in clinical trials. The combination different proving satisfactory promising. In view challenges immunotherapy resistance glioblastomas, treatment these tumors requires further efforts. this review, we explore obstacles that potentially influence efficacy response should be taken into account This article provides a comprehensive review vaccine therapy for glioblastoma. addition, identify main biomarkers, isocitrate dehydrogenase, epidermal growth factor receptor, telomerase reverse transcriptase, known as potential targets glioblastoma, well current status paper also lists proposed solutions overcome facing glioblastomas.
Language: Английский
Citations
5
Cancer Science, Journal Year: 2024, Volume and Issue: 115(4), P. 1048 - 1059
Published: Feb. 21, 2024
With significant advances in analytical technologies, research the field of cancer immunotherapy, such as adoptive T cell therapy, vaccine, and immune checkpoint blockade (ICB), is currently gaining tremendous momentum. Since efficacy immunotherapy recognized only by a minority patients, more potent tumor-specific antigens (TSAs, also known neoantigens) predictive markers for treatment response are great interest. In immunity, immunopeptides, presented human leukocyte antigen (HLA) class I, play role initiating mediators immunogenicity. The latest advancement interdisciplinary multiomics approach has rapidly enlightened us about identity "dark matter" associated immunopeptides. this field, mass spectrometry (MS) viable option to select because naturally processed actually TSA candidates order grasp whole picture immunopeptidome. past few years search space been enlarged approach, sensitivity spectrometers improved, deep/machine-learning-supported peptide algorithms have taken immunopeptidomics next level. review, along with introduction key technical advancements immunopeptidomics, potential further directions will be reviewed from perspective immunotherapy.
Language: Английский
Citations
4
Vaccines, Journal Year: 2024, Volume and Issue: 12(5), P. 533 - 533
Published: May 13, 2024
Merkel cell carcinoma is a rare, aggressive skin cancer that mainly occurs in elderly and immunocompromised patients. Due to the success of immune checkpoint inhibition MCC, importance immunotherapy vaccines MCC has increased recent years. In this article, we aim present current progress perspectives development for disease. Here, summarize discuss literature ongoing clinical trials investigating against MCC. We identified 10 articles through PubMed search vaccine From international trial database Clinical.Trials.gov, nine studies on management which seven are actively recruiting. Most preclinical or phase 1/2 trials. The principles included DNA- (synthetic) peptide-based vaccines, but RNA-based oncolytic viruses, combination also under investigation treatment Although changing, when compared times before approval inhibitors, it will still take some time first ready approval.
Language: Английский
Citations
4
Biomedicines, Journal Year: 2025, Volume and Issue: 13(1), P. 168 - 168
Published: Jan. 12, 2025
Background/Objectives: It remains challenging to treat recurrent ovarian cancer effectively as traditional interventions like chemotherapy and surgery have limited long-term efficacy, highlighting an urgent need for innovative approaches. Immunotherapy offers potential advantages in modulating the immune response against tumor cells has emerged a promising strategy management. This review discusses various immunotherapy modalities, including active passive strategies, cancer. Methods: We systematically reviewed recent advances cancer, efficacy mechanisms of single dual checkpoint inhibitors, inhibitor combinations with or radiotherapy, anti-angiogenic agents, PARP antibody–drug conjugates (ADC), vaccines, adoptive cell therapies (ACT). Additionally, we assessed emerging research on biomarkers predictive responsiveness Results: The findings indicate that immunotherapy, particularly involving inhibitors other demonstrates some showing enhanced benefits specific subtypes. microenvironment platinum-sensitive -resistant cases exhibits distinct immunological profiles, influencing therapy outcomes. Several been identified, potentially aiding patient stratification treatment optimization. Conclusions: significantly treatment, improving Further characteristics is crucial personalizing approaches enhancing their managing
Language: Английский
Citations
0
Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(4), P. 1170 - 1170
Published: Feb. 11, 2025
Viral infections such as human papillomavirus (HPV) and Epstein–Barr virus (EBV) play a critical role in the onset of oropharyngeal (OPC) nasopharyngeal cancer (NPC), respectively. Despite advancements targeted therapies immunotherapies, recurrent/metastatic setting, these tumors remain incurable diseases with poor prognosis. The development therapeutic tumor vaccines, utilizing either neoantigens or oncoviral antigens, represents promising addition to immunotherapy arsenal. Research on vaccine-based for OPC NPC focuses targeting viral particularly HPV E6/E7 EBV EBNA1/LMP2. potential vaccine platforms, including peptide-based, DNA, RNA, vector-based induce durable immune responses against antigens is reported. early-phase clinical trials evaluating HPV-related EBV-related revealed safety preliminary signs efficacy; however, further are crucial validation. This review provides an overview current landscape strategies NPC, discussing their biological mechanisms processes involved anti-HPV anti-EBV treatments, particular focus factors that influence therapies.
Language: Английский
Citations
0
International Immunopharmacology, Journal Year: 2025, Volume and Issue: 151, P. 114261 - 114261
Published: Feb. 26, 2025
Language: Английский
Citations
0
Vaccines, Journal Year: 2025, Volume and Issue: 13(3), P. 296 - 296
Published: March 11, 2025
Background: The therapeutic blockade of the PD1/PD-L1 axis with monoclonal antibodies has led to a breakthrough in cancer treatment, as it plays key role immune evasion tumors. Nevertheless, treating patients vaccines that stimulate targeted response is another attractive approach for which few side effects have been observed combination immunotherapy clinical trials. In this sense, our group recently developed vaccine candidate called PKPD-L1Vac contains an antigen extracellular domain human PD-L1 fused 47 amino-terminal, part LpdA gene N. meningitides, produced E. coli. investigation potential toxicities associated by new therapy preclinical studies critical optimizing efficacy and safety therapy. Methods: Here, we describe immunogenicity preliminary mice, rats, rabbits, non-human primates make use 200 μg dose PKPD-L1 VSSPs or alum phosphate contribute assessment adverse events are relevant future development program novel candidate. Results: administration four species at doses studied was immunogenic did not result behavioral, clinical, hematological, serum biochemical changes. Conclusions: Therefore, could be considered suitable further complex toxicological way its evaluation humans opened.
Language: Английский
Citations
0
Cancer Letters, Journal Year: 2025, Volume and Issue: unknown, P. 217640 - 217640
Published: March 1, 2025
Language: Английский
Citations
0